Insulet's Omnipod 5 System is now compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the United States.

The added compatibility with Abbott’s FreeStyle Libre 2 Plus will open Insulet’s pump to more of the US diabetes market, ...

Insulet's financials are robust, with rising revenues, margins, and a strong cash position. Click here to read an analysis of ...

Abbott modified its original FreeStyle Libre 2 for the purpose of integration with automated insulin delivery systems. It ...

Dexcom and ŌURA have partnered to integrate Dexcom's glucose biosensing feature with the ŌURA Ring's health metrics to help ...

周五，Citi将Insulet Corporation (NASDAQ:PODD)的股票目标价从275美元上调至283美元，同时重申对该股的买入评级。Insulet Corporation报告了2024年强劲的第三季度业绩，收入达到5.439亿美元，剔除汇率影响后增长25.4%，超过了公司18-21%的指引和5.188亿美元的市场预期。 公司在美国的Omnipod销售增长23.4%，这得益于FDA ...

Insulet ’s PODD robust execution to expand the Omnipod 5 platform globally is a tailwind. The company is also capitalizing on ...

Allie Goecke-Butler didn't choose to get diabetes at 24 and become insulin dependent, but yet she says, "staying alive is becoming more and more expensive." ...

The iLet and FreeStyle Libre 3 Plus sensor are also available through durable medical equipment providers. By simply updating the iLet app and software, iLet users will have a choice of iCGMs ...

In March, the FDA cleared Dexcom’s Stelo, making it the first glucose biosensor that doesn’t require a prescription. The small, wearable device, worn on the back of the upper arm, is designed ...

The Omnipod 5 with the Dexcom G7 CGM. [Image courtesy of Insulet] Insulet (Nasdaq:PODD) today announced the full market release of the Omnipod 5 automated insulin delivery app for iPhone in the U.S.

The Omnipod 5 App for iPhone is currently compatible with the Dexcom G6 Continuous Glucose Monitoring (CGM) System and is expected to be compatible with the Dexcom G7 CGM in the U.S. in 2025. The ...